CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

N/ANo Longer AvailableNCT05014724

UCB Biopharma SRL

Overview

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Study Type

EXPANDED_ACCESS

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions

RozanolixizumabDRUG

Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient who has taken part in the CIDP04 (NCT04051944) study * Patient who derives continued benefit from treatment * All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records * Patient is not pregnant Exclusion Criteria:

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.